Highest-materiality recent filing
Sagimet director Tim Walbert resigns; annual meeting ratifies board and auditor
Tim Walbert resigned from Board effective June 12, 2026, citing other commitments, no disagreement.
Sagimet awards 450k options and 450k PSUs to CEO, CFO, and Chief Legal Officer
CEO David Happel receives 300,000 options and 300,000 PSUs at $7.27 exercise price.
Sagimet Q1 net loss $10.7M; $175M April financing; Phase 3 acne trial H2 2026
Net loss $10.7M for Q1 2026 vs $18.2M in Q1 2025; R&D expense $7.0M (down from $15.3M YoY).
Sagimet Biosciences prices public offering of 29.2M shares at $6.00/share for ~$164.5M net proceeds
Offering of 29,166,700 shares of common stock at $6.00 per share; net proceeds expected $164.5 million.
Sagimet pivots to acne, pauses MASH; cash $104.5M; Phase 3 acne trial H2 2026
Preliminary cash balance $104.5M as of Mar 31, 2026; provides runway for strategic pivot.
Sagimet updates investor presentation; no specifics disclosed
Filed Item 7.01 with investor presentation dated April 2026.
Sagimet Biosciences CMO Eduardo Martins retires; Andreas Grauer appointed as replacement
CMO Eduardo Martins retired effective April 20, 2026; will remain as external scientific advisor.
Sagimet Biosciences Reports 2025 Financial Results and MASH/Acne Program Updates
Cash and marketable securities $113.1M; net loss $51M for full year 2025.
Sagimet's partner Ascletis reports positive Phase 3 open-label 52-week acne data for denifanstat
240 subjects received oral denifanstat 50 mg once daily for up to 40 weeks; 52 weeks total for prior denifanstat patients.
Sagimet announces positive Phase 1 PK data for denifanstat/resmetirom combo in MASH
Phase 1 PK trial (NCT07216313) of denifanstat + resmetirom in 40 healthy adults met objectives; combination well-tolerated, no SAEs.
Sagimet enters global exclusive license with TAPI for innovative resmetirom API for FDC program
License grants Sagimet exclusive global rights to TAPI's innovative forms of resmetirom API for fixed-dose combination with denifanstat.
Sagimet reports Q3 2025 net loss $12.9M; advances denifanstat + resmetirom combo trial
Net loss for Q3 2025 was $12.9M vs $14.6M YoY; nine-month net loss $41.5M vs $29.4M.
Sagimet updates investor presentation highlighting MASH, acne, and cancer pipeline
Presentation dated October 23, 2025, targets metabolic dysfunction with novel therapies for MASH, acne, and cancer.
Sagimet appoints KPMG as auditor, dismisses Deloitte; no disagreements reported
Audit Committee and Board approved KPMG as independent auditor for FY 2025 and dismissed Deloitte effective August 18, 2025.
Up to $75M in common stock may be sold from time to time via at-the-market offerings through Leerink Partners.
Sagimet Q2 net loss $10.4M, cash $135.5M; denifanstat meets all acne Phase 3 endpoints
Net loss Q2 2025 $10.4M vs $8.1M; H1 loss $28.6M vs $14.7M; R&D and G&A both increased.
Sagimet amends executive severance agreements with CEO, CFO, and NEO
CEO David Happel gets 24 months base salary, target bonus, equity acceleration on change-in-control termination.
Denifanstat (50mg once daily) met all primary and secondary endpoints vs placebo in Phase 3 acne trial (n=480) in China.
Q1 net loss $18.2M (vs $6.6M Q1 2024); R&D expense $15.3M (vs $5.3M). Cash $144.6M.
Sagimet Biosciences director Merdad Parsey will not stand for re-election at 2025 annual meeting
Merdad Parsey, M.D., Ph.D., notified Board on April 29, 2025 he will not seek re-election at the 2025 Annual Meeting scheduled June 9, 2025.
Full year 2024 net loss $45.6M ($27.9M in 2023); R&D expense $38.4M, up from $19.8M.
Sagimet's second FASN inhibitor TVB-3567 gets IND clearance for acne
FDA's Division of Dermatology and Dentistry cleared IND for TVB-3567, a small molecule FASN inhibitor.
Sagimet files updated investor presentation; no specific material changes disclosed
Filed an updated slide presentation dated February 14, 2025, for use in investor meetings.
Sagimet issues updated January 2025 investor slide deck on MASH, acne, and cancer pipeline
Updated slide presentation dated January 2025 addresses metabolic dysfunction therapies for MASH, acne, and oncology.
Sagimet Q3 2024 net loss $14.6M; cash $170M; denifanstat Phase 3 start expected by end of 2024
Net loss of $14.6M for Q3 2024, vs $6.4M in Q3 2023; R&D expense increased to $12.7M.
Sagimet Biosciences enters into $75M ATM equity sales agreement with Cantor Fitzgerald
Controlled Equity Offering Sales Agreement with Cantor Fitzgerald dated August 15, 2024.
Sagimet Q2 net loss $8.1M, cash $188.5M; denifanstat fibrosis data positive; Phase 3 plan H2 2024
Cash and marketable securities $188.5M as of June 30, 2024; net loss $8.1M for Q2 2024 vs $6.8M year ago.
Sagimet Biosciences expands board to 9, appoints Jennifer Jarrett and Dr. Anne Phillips as directors
Board expanded from 7 to 9 directors; appointments effective August 1, 2024.
Sagimet updates investor presentation; no material financial or clinical data changes
Company filed updated slide presentation for investor meetings dated July 2, 2024.
Sagimet reports positive Phase 2b MASH data for denifanstat; primary endpoints met
Primary endpoints achieved: ≥2-point NAS reduction without fibrosis worsening (38% vs 16%, p=0.0035) and MASH resolution (26% vs 11%, p=0.0173) in ITT.
Sagimet reports positive FASCINATE-2 Phase 2b data; denifanstat meets primary endpoints in MASH
Primary endpoint: MASH resolution with ≥2-point NAS reduction without worsening fibrosis: 38% denifanstat vs 16% placebo (p=0.0035) in ITT.
Sagimet Biosciences updates investor presentation; no new material data disclosed
Filed an updated slide presentation as Exhibit 99.1 under Item 7.01 Regulation FD Disclosure.
Net loss for Q1 2024 was $6.6M, flat year-over-year; R&D expense $5.3M, G&A $3.5M.
Sagimet Biosciences appoints Thierry Chauche as CFO, effective May 6, 2024
Thierry Chauche named CFO, replacing interim CFO Joseph Oriti who resigned.
Sagimet FY2023 net loss $27.9M; denifanstat Phase 2b hits endpoints; board adds Walbert, Hoelscher
Net loss $27.9M for FY2023 vs $30.5M in 2022; revenue $2.0M from milestone payment.
Sagimet CFO Rimac resigns; Oriti appointed interim CFO & PFO
Anthony Rimac resigned as CFO effective January 31, 2024; previously disclosed.
Sagimet Biosciences prices public offering of 9M shares at $12.50/share, raising $112.5M gross
Priced 9,000,000 shares of Series A common stock at $12.50/share; gross proceeds ~$112.5M before expenses.
Sagimet Biosciences reports preliminary cash of $94.9M as of Dec 31, 2023
Cash, cash equivalents and short-term investments estimated at ~$94.9M.
NASH resolution without worsening fibrosis (≥2-point NAS reduction): 36% denifanstat vs 13% placebo (p=0.0022).
CFO Anthony Rimac to resign Jan. 31, 2024; interim appointments from Stout
CFO Anthony Rimac resigns effective Jan. 31, 2024 for personal reasons; no disagreement with company or auditors.
Sagimet Biosciences grants RSUs to executives post-IPO; CEO Happel receives 624,910 units
Board approved RSU grants: CEO David Happel (624,910), Eduardo Martins (89,570), George Kemble (150,750).
Sagimet reports Q3 net loss of $6.4M; cash $101.8M; NASH data due Q1 2024
Net loss $6.4M vs $7.5M in Q3 2022; revenue $2.0M from milestone vs zero year-ago.
Sagimet furnishes updated investor presentation on NASH, acne, cancer pipeline
Filed updated slide deck under Item 7.01 for use in investor meetings.
Sagimet partner Ascletis enrolls 120 patients in Phase 3 trial of denifanstat for rGBM
Ascletis completed enrollment of 120 patients in Phase 3 registration trial of denifanstat plus bevacizumab for recurrent glioblastoma.
Sagimet Q2 net loss $6.8M; IPO raised $86.2M net; denifanstat 67% fat reduction
IPO closed July 18: 6,026,772 shares at $16; gross proceeds $96.4M, net $86.2M.
Sagimet posts updated investor presentation on NASH, acne, cancer pipeline
Company furnished investor slide deck dated August 10, 2023; no financial results disclosed.
Sagimet Biosciences names Anthony Rimac CFO effective August 1, 2023
Anthony Rimac appointed CFO, principal financial and accounting officer, effective Aug 1, 2023.
Sagimet Biosciences closes IPO; files amended charter and bylaws effective July 18, 2023
Authorized 500M shares of Series A common stock and 15M shares of Series B common stock.
On June 12, 2026, Tim Walbert, a member of the Board of Directors (the “Board”) of Sagimet Biosciences Inc. (the “Company”), tendered his resignation from the Board, effective as of June 12, 2026.
On April 29, 2025 Merdad Parsey, M.D., Ph.D., current member of the board of directors (the “Board”) of Sagimet Biosciences Inc. (the “Company”), notified the Board that he will not stand for re-election at the Company’s 2025 Annual Meeting of Stockholders (the “Annual Meeting”), currently scheduled to be held on June 9, 2025.
the board of directors (the “Board”) of Sagimet Biosciences Inc. (the “Company”) approved the expansion of the Board from seven directors to nine directors and the appointment of each of Jennifer Jarrett and Dr. Anne Phillips to serve as directors of the Board, in each case, effective as of August 1, 2024
the board of directors (the “Board”) of Sagimet Biosciences Inc. (the “Company”) approved the expansion of the Board from seven directors to nine directors and the appointment of each of Jennifer Jarrett and Dr. Anne Phillips to serve as directors of the Board, in each case, effective as of August 1, 2024
On May 3, 2024, the Board of Directors (the “Board”) of Sagimet Biosciences Inc. (the “Company”) appointed Thierry Chauche as the Company’s Chief Financial Officer, effective May 6, 2024.
On May 5, 2024, Joseph Oriti, the Company’s interim Principal Financial Officer and interim Principal Accounting Officer resigned in connection with Mr. Chauche’s appointment.
the appointment of each of Tim Walbert and Paul Hoelscher to serve as directors of the Board, in each case effective as of April 1, 2024
the appointment of each of Tim Walbert and Paul Hoelscher to serve as directors of the Board, in each case effective as of April 1, 2024
On December 28, 2023, Anthony Rimac, the Chief Financial Officer of Sagimet Biosciences Inc. (the “ Company ”) provided notice of his intent to resign effective January 31, 2024.
On January 31, 2024, the board of directors (the “ Board ”) of the Company appointed Joseph Oriti as Interim Principal Financial Officer and Interim Principal Accounting Officer, effective as of February 1, 2024 (the “ Effective Date ”).
Anthony Rimac provided notice of his intent to step down as the Chief Financial Officer of Sagimet Biosciences Inc. (the “ Company ”) effective January 31, 2024.
Gaeton Biscardi, Managing Director of Stout, will be serving as the Company’s Interim VP of Finance during this transition period
Max materiality 0.85 · Median 0.60 · Most common event other_material